Our Projects
BEAM - Establishment of EEG biomarkers for the treatment of psychiatric disorders
We participated in the BEAM study from June 2020 to June 2022. We carried out this study in-office and used our database for participant recruitment. We successfully screened 39 participants and enrolled 36 participants.
ALTO-100-001 - An open-label study of ALTO-100 in adults with major depressive disorder and/or post-traumatic stress disorder
We participated in the ALTO-100-001 study from December 2021 to August 2022. We carried out this study in-office and used our database for participant recruitment. We successfully screened 29 participants and enrolled 19 participants.
RECOVER - A prospective, multicenter, randomized controlled blinded trial demonstrating the safety and effectiveness of VNS Therapy® System as adjunctive therapy versus a no-stimulation control in subjects with treatment-resistant depression
We started participating in the RECOVER study in April 2022. We are carrying out this study in-office and are using our database for participant recruitment. We have successfully screened 4 participants.
ALTO-100-003 - An open-label study of ALTO-100 in adults with major depressive disorder
We participated in the ALTO-100-003 study from June 2022 to September 2022. We carried out the study remotely and used the sponsor's database for participant recruitment. We successfully screened 65 participants and enrolled 21 participants.
ALTO-300-004 - An open-label study of ALTO-300 in adults with major depressive disorder
We participated in ALTO-300-004 from September 2022 to January 2023. We carried out the study remotely and used the sponsor's database for participant recruitment. We successfully screened 190 participants and enrolled 52 participants. For this study, we exceeded our enrollment goal 4 months ahead of schedule.
ALTO-100-201 - A randomized, double-blind, placebo-controlled study of ALTO-100 with an open-label extension in adults with major depressive disorder
We just recently were activated for ALTO-100-201 and we will participate in both a decentralized version and an in-office version of this study.